Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
SurModics (SRDX) PT Lowered to $63 at Needham & Company
November 1, 2019 7:30 AM EDTNeedham & Company analyst Mike Matson lowered the price target on SurModics (NASDAQ: SRDX) to $63.00 (from $68.00) while maintaining a Buy rating.
The analyst commented, "Full data from GALACTIC-HF remains on track for 2021. We continue to view omecamtiv as the backbone to our CYTK... More
SurModics (SRDX) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
October 31, 2019 4:17 PM EDTSurModics (NASDAQ: SRDX) reported Q4 EPS of $0.37, in-line with the analyst estimate of $0.37. Revenue for the quarter came in at $30.8 million versus the consensus estimate of $28.36 million.
Summary of Fourth Quarter and Recent Highlights
Revenue of $30.8 million, an increase of 33.8% year-over-yearGAAP EPS of $0.26, non-GAAP EPS of $0.37Completed enrollment in TRANSCEND pivotal clinical trial for... More